• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对转移性去势抵抗性前列腺癌的热休克蛋白。

Targeting heat shock proteins in metastatic castration-resistant prostate cancer.

机构信息

Department of Medical Oncology, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada.

The Vancouver Prostate Centre, 2775 Laurel Street, 6th Floor, Vancouver, BC V5Z 1M9, Canada.

出版信息

Nat Rev Urol. 2015 Jan;12(1):26-36. doi: 10.1038/nrurol.2014.320. Epub 2014 Dec 16.

DOI:10.1038/nrurol.2014.320
PMID:25512207
Abstract

The survival of malignant cells is constantly threatened by a myriad of cellular insults. In the context of such proteotoxic stress, cancer cells activate cytoprotective adaptive pathways. Heat shock proteins (HSPs) are highly conserved molecular chaperones that are expressed at low levels under normal conditions, but upregulated by cellular stress. As molecular chaperones, HSPs control the stability and function of client proteins, preventing aggregation of misfolded proteins, facilitating intracellular protein trafficking, maintaining protein conformation to enable ligand binding, phosphorylating proteins in signalling complexes and degrading severely damaged proteins via the ubiquitin-proteasome pathway. A key client protein of several HSPs is the androgen receptor (AR). HSPs facilitate binding of dihydrotestosterone to the AR, and enhance AR-mediated transcriptional activity. The integral role of HSPs in AR function speaks to their potential utility as therapeutic targets in castration-resistant prostate cancer (CRPC), a disease state characterized by persistent activation of the androgen-AR axis. Inhibition of HSPs has the additional benefit of potentially modulating signalling and transcriptional networks that are associated with HSP client proteins in CRPC cells. As a consequence, HSPs represent highly attractive targets in the development of treatments for CRPC.

摘要

恶性细胞的生存不断受到各种细胞损伤的威胁。在这种蛋白毒性应激的情况下,癌细胞会激活细胞保护适应性途径。热休克蛋白(HSPs)是高度保守的分子伴侣,在正常情况下表达水平较低,但在细胞应激下上调。作为分子伴侣,HSPs 控制着客户蛋白的稳定性和功能,防止错误折叠蛋白的聚集,促进细胞内蛋白运输,维持蛋白构象以允许配体结合,磷酸化信号复合物中的蛋白,并通过泛素-蛋白酶体途径降解严重受损的蛋白。几种 HSP 的关键客户蛋白是雄激素受体(AR)。HSPs 促进二氢睾酮与 AR 的结合,并增强 AR 介导的转录活性。HSPs 在 AR 功能中的重要作用表明,它们有可能成为去势抵抗性前列腺癌(CRPC)的治疗靶点,这种疾病状态的特征是雄激素-AR 轴持续激活。抑制 HSPs 还有可能调节与 CRPC 细胞中 HSP 客户蛋白相关的信号和转录网络。因此,HSPs 是开发治疗 CRPC 方法的极具吸引力的靶点。

相似文献

1
Targeting heat shock proteins in metastatic castration-resistant prostate cancer.针对转移性去势抵抗性前列腺癌的热休克蛋白。
Nat Rev Urol. 2015 Jan;12(1):26-36. doi: 10.1038/nrurol.2014.320. Epub 2014 Dec 16.
2
Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.治疗抵抗性前列腺癌中雄激素受体蛋白稳定性的干扰。
Int J Cancer. 2019 Apr 15;144(8):1775-1779. doi: 10.1002/ijc.31818. Epub 2018 Nov 4.
3
Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.雄激素受体的利用克服晚期前列腺癌中的紫杉烷耐药性。
Adv Cancer Res. 2015;127:123-58. doi: 10.1016/bs.acr.2015.03.001. Epub 2015 Mar 29.
4
Androgen receptors in hormone-dependent and castration-resistant prostate cancer.雄激素受体在激素依赖性和去势抵抗性前列腺癌中的作用。
Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13.
5
Heat shock proteins in cancer: targeting the 'chaperones'.热休克蛋白在癌症中的作用:靶向“伴侣蛋白”。
Future Med Chem. 2012 May;4(7):927-35. doi: 10.4155/fmc.12.50.
6
Heat shock and other apoptosis-related proteins as therapeutic targets in prostate cancer.热休克蛋白和其他与细胞凋亡相关的蛋白作为前列腺癌的治疗靶点。
Asian J Androl. 2014 May-Jun;16(3):359-63. doi: 10.4103/1008-682X.126400.
7
Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.同时靶向雄激素受体(AR)和热休克蛋白90(HSP90)可抑制前列腺癌细胞生长并防止耐药机制的产生。
Endocr Relat Cancer. 2015 Oct;22(5):805-18. doi: 10.1530/ERC-14-0541. Epub 2015 Jul 17.
8
Stromal factors involved in human prostate cancer development, progression and castration resistance.参与人类前列腺癌发生、发展和去势抵抗的基质因素。
J Cancer Res Clin Oncol. 2017 Feb;143(2):351-359. doi: 10.1007/s00432-016-2284-3. Epub 2016 Oct 27.
9
Targeting heat shock proteins in prostate cancer.靶向前列腺癌中的热休克蛋白。
Curr Med Chem. 2013;20(22):2731-40. doi: 10.2174/0929867311320220001.
10
Role of BET proteins in castration-resistant prostate cancer.BET蛋白在去势抵抗性前列腺癌中的作用。
Drug Discov Today Technol. 2016 Mar;19:29-38. doi: 10.1016/j.ddtec.2016.07.001. Epub 2016 Jul 30.

引用本文的文献

1
PROTAC technology for prostate cancer treatment.用于前列腺癌治疗的PROTAC技术。
Acta Mater Med. 2025 Jan 7;4(1):99-121. doi: 10.15212/amm-2024-0075. Epub 2025 Jan 30.
2
A mitochondrial outer membrane protein TOMM20 maintains protein stability of androgen receptor and regulates AR transcriptional activity in prostate cancer cells.一种线粒体外膜蛋白TOMM20维持雄激素受体的蛋白稳定性,并调节前列腺癌细胞中的AR转录活性。
Oncogene. 2025 Jun;44(21):1567-1577. doi: 10.1038/s41388-025-03328-w. Epub 2025 Mar 6.
3
Canonical and noncanonical NOTCH signaling in the nongenetic resistance of cancer: distinct and concerted control.

本文引用的文献

1
Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.使用OGX - 427抑制热休克蛋白27可诱导内质网应激,并增强热休克蛋白90抑制剂对去势抵抗性前列腺癌的延缓作用。
Eur Urol. 2014 Jul;66(1):145-55. doi: 10.1016/j.eururo.2013.12.019. Epub 2013 Dec 29.
2
Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.靶向雄激素受体和簇蛋白通过抑制适应性应激反应和 AR 稳定性延迟去势抵抗性前列腺癌的进展。
Cancer Res. 2013 Aug 15;73(16):5206-17. doi: 10.1158/0008-5472.CAN-13-0359. Epub 2013 Jun 20.
3
癌症非遗传抗性中的经典和非经典NOTCH信号传导:独特且协同的调控
Front Med. 2025 Feb;19(1):23-52. doi: 10.1007/s11684-024-1107-1. Epub 2025 Jan 2.
4
Targeting CDK7 enhances the antitumor efficacy of enzalutamide in androgen receptor-positive triple-negative breast cancer by inhibiting c-MYC-mediated tumorigenesis.靶向CDK7通过抑制c-MYC介导的肿瘤发生增强恩杂鲁胺在雄激素受体阳性三阴性乳腺癌中的抗肿瘤疗效。
Mol Cancer Ther. 2024 Nov 26. doi: 10.1158/1535-7163.MCT-23-0386.
5
Functional and therapeutic significant of heat-shock protein 90 (HSP90) in reproductive cancers.热休克蛋白90(HSP90)在生殖系统癌症中的功能及治疗意义
Clin Transl Oncol. 2025 May;27(5):1933-1942. doi: 10.1007/s12094-024-03743-7. Epub 2024 Oct 6.
6
Extract Induces Apoptosis via Generation of Reactive Oxygen Species and Inhibition of Heat Shock Protein 27 and Androgen Receptor in Prostate Cancers.提取物通过产生活性氧以及抑制前列腺癌中的热休克蛋白27和雄激素受体来诱导细胞凋亡。
Int J Mol Sci. 2024 Feb 28;25(5):2799. doi: 10.3390/ijms25052799.
7
The role of HSP40 in cancer: Recent advances.HSP40 在癌症中的作用:最新进展。
Histol Histopathol. 2024 Jul;39(7):845-851. doi: 10.14670/HH-18-693. Epub 2023 Dec 19.
8
Clinical implications of heat shock protein 70 in oral carcinogenesis and prediction of progression and recurrence in oral squamous cell carcinoma patients: a retrospective clinicopathological study.热休克蛋白 70 在口腔癌发生中的临床意义及其对口腔鳞状细胞癌患者进展和复发的预测:一项回顾性临床病理研究。
Eur J Med Res. 2023 Oct 27;28(1):464. doi: 10.1186/s40001-023-01433-8.
9
International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.国际基础与临床药理学联盟第十三分会:核受体超家族-2023 更新。
Pharmacol Rev. 2023 Nov;75(6):1233-1318. doi: 10.1124/pharmrev.121.000436. Epub 2023 Aug 16.
10
AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer.AR 拮抗剂通过 TOMM20 自噬降解促进的转化发展为神经内分泌前列腺癌,从而产生药物耐药性。
J Exp Clin Cancer Res. 2023 Aug 10;42(1):204. doi: 10.1186/s13046-023-02776-0.
The role of heat shock proteins in bladder cancer.
热休克蛋白在膀胱癌中的作用。
Nat Rev Urol. 2013 Jul;10(7):386-95. doi: 10.1038/nrurol.2013.108. Epub 2013 May 14.
4
Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer.Hsp27 调节前列腺癌中的上皮间质转化、转移和循环肿瘤细胞。
Cancer Res. 2013 May 15;73(10):3109-19. doi: 10.1158/0008-5472.CAN-12-3979. Epub 2013 Mar 14.
5
Mini-review: Foldosome regulation of androgen receptor action in prostate cancer.综述:小折叠体调节前列腺癌细胞中雄激素受体的作用
Mol Cell Endocrinol. 2013 Apr 30;369(1-2):52-62. doi: 10.1016/j.mce.2013.01.023. Epub 2013 Feb 8.
6
The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer.热休克蛋白抑制剂在治疗去势抵抗性前列腺癌中的应用前景。
Curr Opin Urol. 2013 May;23(3):194-200. doi: 10.1097/MOU.0b013e32835e9f1a.
7
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.Hsp90 抑制剂 ganetespib 在前列腺癌细胞中的有效活性,与雄激素受体状态或变体受体表达无关。
Int J Oncol. 2013 Jan;42(1):35-43. doi: 10.3892/ijo.2012.1698. Epub 2012 Nov 14.
8
Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer.库替森(OGX-011):一种处于研发阶段的第二代簇蛋白反义抑制剂,用于治疗前列腺癌。
Future Oncol. 2012 Oct;8(10):1239-51. doi: 10.2217/fon.12.129.
9
Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer.分泌型热休克蛋白 90 是前列腺癌上皮间质转化(EMT)的新型调节因子。
J Biol Chem. 2012 Nov 2;287(45):37732-44. doi: 10.1074/jbc.M112.389015. Epub 2012 Sep 18.
10
Clusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells.簇集蛋白通过 Twist1 介导 TGF-β诱导的前列腺癌细胞上皮-间充质转化和转移。
Cancer Res. 2012 Oct 15;72(20):5261-72. doi: 10.1158/0008-5472.CAN-12-0254. Epub 2012 Aug 15.